Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 4fludarabine phosphate 2aldesleukin 2Paclitaxel 2Nivolumab 2Bevacizumab 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1fludarabine 1durvalumab 1dostarlimab 1belzutifan 1alovudine 1Watchful Waiting 1Vaccines, Synthetic 1VGX-3100 1Therapeutic Touch 1Specimen Handling 1Ritonavir 1Radiosurgery 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Papillomavirus Vaccines 1Observation 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vaginal Neoplasms × Fondaparinux × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡